GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. - Xu Y; Li Y; Cheng Z; Shao C; Zhao X; Liu Y; Gou X; Li C (Drug design, development and therapy, 2026)